NVAX vs SNY vs PFE vs GSK vs JNJ

For growth investors, Novavax, Inc.

(NVAX) is the stronger pick with 64. 7% revenue growth year-over-year, versus -1. 6% for Pfizer Inc. (PFE). Novavax, Inc. (NVAX) offers the better valuation at 4. 0x trailing P/E, making it the more compelling value choice. Analysts rate Novavax, Inc. (NVAX) a "Buy" — based on 23 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

On trailing P/E, Novavax, Inc.

(NVAX) is the cheapest at 4. 0x versus Johnson & Johnson at 38. 2x. On forward P/E, Pfizer Inc. is actually cheaper at 8. 7x — notably different from the trailing picture, reflecting expected earnings growth. The PEG ratio (P/E divided by earnings growth rate) is the most growth-adjusted single valuation metric: GSK plc wins at 0. 73x versus Johnson & Johnson's 34. 02x — a PEG below 1. 0 traditionally signals the market is underpricing earnings growth.

Over the past 5 years, GSK plc (GSK) delivered a total return of +52.

6%, compared to -93. 7% for Novavax, Inc. (NVAX). Over 10 years, the gap is even starker: JNJ returned +131. 3% versus NVAX's -89. 4%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), Johnson & Johnson (JNJ) is the lower-risk stock at 0.

04β versus Novavax, Inc. 's 2. 22β — meaning NVAX is approximately 4853% more volatile than JNJ relative to the S&P 500. On balance sheet safety, Sanofi (SNY) carries a lower debt/equity ratio of 30% versus 111% for GSK plc — giving it more financial flexibility in a downturn.

By revenue growth (latest reported year), Novavax, Inc.

(NVAX) is pulling ahead at 64. 7% versus -1. 6% for Pfizer Inc. (PFE). On earnings-per-share growth, the picture is similar: GSK plc grew EPS 348. 4% year-over-year, compared to -57. 8% for Johnson & Johnson. Over a 3-year CAGR, SNY leads at 4. 8% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

Novavax, Inc.

(NVAX) is the more profitable company, earning 39. 2% net margin versus 12. 4% for Pfizer Inc. — meaning it keeps 39. 2% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: NVAX leads at 50. 1% versus 13. 6% for SNY. At the gross margin level — before operating expenses — NVAX leads at 93. 7%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

The PEG ratio (forward P/E divided by expected earnings growth rate) is the most precise measure of undervaluation relative to growth potential.

By this metric, GSK plc (GSK) is the more undervalued stock at a PEG of 0. 73x versus Johnson & Johnson's 34. 02x. A PEG below 1. 0 is traditionally considered the threshold for growth-adjusted undervaluation. On forward earnings alone, Pfizer Inc. (PFE) trades at 8. 7x forward P/E versus 19. 1x for Johnson & Johnson — 10. 5x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for NVAX: 78. 0% to $18. 00.

In this comparison, PFE (6.

7% yield), GSK (6. 6% yield), SNY (5. 1% yield), JNJ (2. 2% yield) pay a dividend. NVAX does not pay a meaningful dividend and should not be held primarily for income.

For long-horizon retirement investors, Johnson & Johnson (JNJ) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0.

04), 2. 2% yield, +131. 3% 10Y return). Novavax, Inc. (NVAX) carries a higher beta of 2. 22 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (JNJ: +131. 3%, NVAX: -89. 4%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.

In terms of investment character: NVAX is a small-cap high-growth stock; SNY is a mid-cap income-oriented stock; PFE is a mid-cap income-oriented stock; GSK is a mid-cap deep-value stock; JNJ is a large-cap quality compounder stock. SNY, PFE, GSK, JNJ pay a dividend while NVAX does not, making them suitable for different income and tax situations. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.